Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pyrotinib for HER2-Positive Advanced Breast Cancer Previously Treated With Trastuzumab and Pertuzumab
Sponsor: Beijing 302 Hospital
Summary
In China, pyrotinib is used for patients with HER2-positive advanced breast cancer who have progressed on trastuzumab. As anti-HER2 antibody therapy has advanced from trastuzumab monotherapy to trastuzumab-pertuzumab dual-target treatment, few clinical studies have investigated pyrotinib's efficacy among patients pre-treated with this dual-antibody regimen. This is a retrospective observational cohort study, which aims to assess the efficacy and safety of pyrotinib in this patient cohort.
Official title: Retrospective Analysis of Pyrotinib in the Treatment of HER2-Positive Advanced Breast Cancer Previously Treated With Trastuzumab and Pertuzumab
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
200
Start Date
2026-09-02
Completion Date
2027-03-30
Last Updated
2026-09-09
Healthy Volunteers
No
Conditions
Interventions
Pyrotinib 400mg
Pyrotinib (400 mg daily)-based treatment
Locations (1)
The Fifth Medical Center of the PLA General Hospital
Beijing, Beijing Municipality, China